Literature DB >> 21536132

Cholesterol-independent neuroprotective and neurotoxic activities of statins: perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders.

D Allan Butterfield1, Eugenio Barone, Cesare Mancuso.   

Abstract

Statins, long known to be beneficial in conditions where dyslipidemia occurs by lowering serum cholesterol levels, also have been proposed for use in neurodegenerative conditions, including Alzheimer disease. However, it is not clear that the purported effectiveness of statins in neurodegenerative disorders is directly related to cholesterol-lowering effects of these agents; rather, the pleiotropic functions of statins likely play critical roles. Moreover, it is becoming more apparent with additional studies that statins can have deleterious effects in preclinical studies and lack effectiveness in various recent clinical trials. This perspective paper outlines pros and cons of the use of statins in neurodegenerative disorders, with particular emphasis on Alzheimer disease. 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21536132      PMCID: PMC3130102          DOI: 10.1016/j.phrs.2011.04.007

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  97 in total

Review 1.  Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide.

Authors:  D A Butterfield; J Drake; C Pocernich; A Castegna
Journal:  Trends Mol Med       Date:  2001-12       Impact factor: 11.951

Review 2.  Statin therapy and autoimmune disease: from protein prenylation to immunomodulation.

Authors:  John Greenwood; Lawrence Steinman; Scott S Zamvil
Journal:  Nat Rev Immunol       Date:  2006-05       Impact factor: 53.106

3.  Gas chromatography-mass spectrometry-based simultaneous quantitative analytical method for urinary oxysterols and bile acids in rats.

Authors:  Bhowmik Salil Kumar; Bong Chul Chung; Young-Joo Lee; Hong Jae Yi; Byung-Hoon Lee; Byung Hwa Jung
Journal:  Anal Biochem       Date:  2010-09-25       Impact factor: 3.365

4.  Reduced risk of incident AD with elective statin use in a clinical trial cohort.

Authors:  D Larry Sparks; Richard J Kryscio; Marwan N Sabbagh; Donald J Connor; Lisa M Sparks; Carolyn Liebsack
Journal:  Curr Alzheimer Res       Date:  2008-08       Impact factor: 3.498

Review 5.  Alzheimer's disease.

Authors:  Henry W Querfurth; Frank M LaFerla
Journal:  N Engl J Med       Date:  2010-01-28       Impact factor: 91.245

6.  Treatment of statin adverse effects with supplemental Coenzyme Q10 and statin drug discontinuation.

Authors:  Peter H Langsjoen; Jens O Langsjoen; Alena M Langsjoen; Lindsay A Lucas
Journal:  Biofactors       Date:  2005       Impact factor: 6.113

7.  Simvastatin attenuates hypomyelination induced by hypoxia-ischemia in neonatal rats.

Authors:  Aiping Li; Shuhong Lv; Zhe Yu; Yumei Zhang; Hui Ma; Hui Zhao; Hua Piao; Shao Li; Nannan Zhang; Changkai Sun
Journal:  Neurol Res       Date:  2010-04-30       Impact factor: 2.448

Review 8.  Statins for the treatment of dementia.

Authors:  Bernadette McGuinness; John O'Hare; David Craig; Roger Bullock; Reem Malouf; Peter Passmore
Journal:  Cochrane Database Syst Rev       Date:  2010-08-04

9.  Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease.

Authors:  Anamitra Ghosh; Avik Roy; Joanna Matras; Saurav Brahmachari; Howard E Gendelman; Kalipada Pahan
Journal:  J Neurosci       Date:  2009-10-28       Impact factor: 6.167

10.  Pravastatin and cognitive function in the elderly. Results of the PROSPER study.

Authors:  Stella Trompet; Peter van Vliet; Anton J M de Craen; Jelle Jolles; Brendan M Buckley; Michael B Murphy; Ian Ford; Peter W Macfarlane; Naveed Sattar; Chris J Packard; David J Stott; Jim Shepherd; Eduard L E M Bollen; Gerard J Blauw; J Wouter Jukema; Rudi G J Westendorp
Journal:  J Neurol       Date:  2009-08-04       Impact factor: 4.849

View more
  28 in total

Review 1.  Blood-brain barrier integrity and glial support: mechanisms that can be targeted for novel therapeutic approaches in stroke.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

2.  Statins stimulate the production of a soluble form of the receptor for advanced glycation end products.

Authors:  Patricia Quade-Lyssy; Anna Maria Kanarek; Markus Baiersdörfer; Rolf Postina; Elzbieta Kojro
Journal:  J Lipid Res       Date:  2013-08-21       Impact factor: 5.922

3.  Effects of statins and cholesterol on memory functions in mice.

Authors:  Ravindra M Ghodke; Nagesh Tour; Kshama Devi
Journal:  Metab Brain Dis       Date:  2012-10-16       Impact factor: 3.584

4.  Inhibition of interferon-beta responses in multiple sclerosis immune cells associated with high-dose statins.

Authors:  Xuan Feng; Diana Han; Bharat K Kilaru; Beverly S Franek; Timothy B Niewold; Anthony T Reder
Journal:  Arch Neurol       Date:  2012-10

5.  Atorvastatin Prevents Cognitive Deficits Induced by Intracerebroventricular Amyloid-β1-40 Administration in Mice: Involvement of Glutamatergic and Antioxidant Systems.

Authors:  Wagner C Martins; Vanessa Valgas dos Santos; Alessandra Antunes dos Santos; Samuel Vandresen-Filho; Tharine A Dal-Cim; Karen A de Oliveira; Claudia B N Mendes-de-Aguiar; Marcelo Farina; Rui Daniel Prediger; Giordano Gubert Viola; Carla I Tasca
Journal:  Neurotox Res       Date:  2015-04-01       Impact factor: 3.911

Review 6.  An overview on therapeutics attenuating amyloid β level in Alzheimer's disease: targeting neurotransmission, inflammation, oxidative stress and enhanced cholesterol levels.

Authors:  Xiaoling Zhou; Yifei Li; Xiaozhe Shi; Chun Ma
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

7.  Amyloid beta (Aβ) peptide modulators and other current treatment strategies for Alzheimer's disease (AD).

Authors:  Walter J Lukiw
Journal:  Expert Opin Emerg Drugs       Date:  2012-03-23       Impact factor: 4.191

Review 8.  Phytosterols and Dementia.

Authors:  Rong Shuang; Xu Rui; Li Wenfang
Journal:  Plant Foods Hum Nutr       Date:  2016-12       Impact factor: 3.921

Review 9.  The 2013 SFRBM discovery award: selected discoveries from the butterfield laboratory of oxidative stress and its sequela in brain in cognitive disorders exemplified by Alzheimer disease and chemotherapy induced cognitive impairment.

Authors:  D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2014-07-01       Impact factor: 7.376

Review 10.  Statins more than cholesterol lowering agents in Alzheimer disease: their pleiotropic functions as potential therapeutic targets.

Authors:  Eugenio Barone; Fabio Di Domenico; D Allan Butterfield
Journal:  Biochem Pharmacol       Date:  2013-11-11       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.